Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792537 | 1.00 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL23088251 | 0.88 | MEN1 (0.45) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL23118466 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1MAPTGAA | |
| Hydrochloric Acid SCHEMBL23088234 | 0.78 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1MAPTGAA | |
| Hydrochloric Acid SCHEMBL29792702 | 0.78 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL23088089 | 0.78 | MEN1 (0.43) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL23139806 | 0.76 | EPAS1 (0.43) | ALDH1A1GAAKDM4ADRD2RPS6KA1 | |
| SCHEMBL23139992 | 0.76 | EPAS1 (0.43) | ALDH1A1GAAMAPK1KDM4ADRD2 | |
| SCHEMBL17785276 | 0.73 | RPS6KA1 (0.55) | MEN1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL23118676 | 0.73 | EPAS1 (0.38) | ALDH1A1GAAKDM4ADRD2RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| WO-2021055621-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | MEN1 633/4885KMT2A 1299/4885ALDH1A1 3007/4885 |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | MEN1 633/4885KMT2A 1299/4885ALDH1A1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.